Phio Pharmaceuticals Corp (PHIO): Market Cap to Revenue

Symbol and logo of brand phiopharma.com (PHIO)

Phio Pharmaceuticals (PHIO) retains a dedicated team of scientists through long-term options, which stabilizes the development of oncology drugs. Competent management effectively protects the intellectual property of the INTASYL platform. Analyzing the P/S market multiple in GURU.Markets, we note that the mark serves as a current business valuation metric. Fundamental patents for carrier-free gene silencing create significant barriers to entry for new players in the sector.

P/S Multiple: Phio Pharmaceuticals Corp (PHIO) for 07/04/2022 - 11/13/2026

Phio Pharmaceuticals (PHIO) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Price Performance Chart phiopharma.com|PHIO - Price Target Chart
- stock exchange capitalization data:
Market Valuation RXi Pharmaceuticals|PHIO - Enterprise Value
- book value of equity indicators:
Book Value per Share Phio Pharmaceuticals|PHIO - Book Capitalization|Market Cap to Net Assets Ratio phiopharma.com|PHIO - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Phio Pharmaceuticals|PHIO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital phiopharma.com|PHIO - Company Total Debt|Debt to Book Capital RXi Pharmaceuticals|PHIO - Company Long-Term Debts|Short-Term Debt Volume Phio Pharmaceuticals|Quick Liquidity Indicator phiopharma.com
- company profitability and valuation multiples indicators:
PHIO - Net Profit|Projected Future Earnings Phio Pharmaceuticals|PHIO - Price to Earnings Ratio|Future Price to Earnings phiopharma.com|PHIO - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio RXi Pharmaceuticals|PHIO - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Phio Pharmaceuticals|PHIO - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months phiopharma.com|PHIO - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Phio Pharmaceuticals
- issuer revenue and sales details:
PHIO - Company Revenue|Company Expected Sales Volume phiopharma.com|PHIO - P/S Multiple|Market Cap to Projected Revenue RXi Pharmaceuticals
Summary company analytics:Phio Pharmaceuticals Corp
Mass-produced product of Phio Pharmaceuticals

An analysis of the credit quality of Phio Pharmaceuticals (PHIO) requires an assessment of market value relative to generated cash flows. Business resilience is supported by inelastic demand for the unique self-delivering RNA strands of the INTASYL platform. This price-to-sales valuation measures the deviation of the current multiple from the statistical norm via standard deviations. An indicator move beyond two sigma boundaries signals potential returns but warns of the risk of a sharp correction.

Competing companies

TEM (Tempus AI) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Qiagen QGEN|IONS - Market Cap to Revenue|Repligen Corp. - P/S Multiple|RNA - P/S Multiple|CRSP: P/S Multiple|Market Cap to Revenue genedx.com|RARE (Ultragenyx) - P/S Multiple|Price to Sales Beam Therapeutics Inc BEAM|Market Cap to Revenue SRPT (Sarepta Therapeutics Inc)|P/S Multiple Twist Bioscience Corp (TWST)|10x Genomics, Inc. - Market Cap to Revenue|Market Cap to Sales Volume NTLA (intelliatx.com)|Stoke Therapeutics, Inc. - P/S Multiple|Price-to-Revenue Coefficient BioLife Solutions Inc BLFS|WVE: P/S Multiple|Market Cap to Revenue Maze Therapeutics Corp|SION (Sionna Therapeutics Inc) - P/S Multiple|P/S Multiple primemedicine.com|Price-to-Revenue Ratio Taysha Gene Therapies, Inc. (TSHA)|Price-to-Revenue Ratio QURE (uniQure NV)|Price-to-Revenue Ratio MeiraGTx PLC MGTX|Price-to-Revenue Coefficient REGENXBIO Corp (RGNX)|SLDB - Price-to-Revenue Ratio|Price-to-Sales Ratio OCGN|PACB: P/S Multiple|Benitec Biopharma Inc - Market Capitalization-to-Revenue Ratio|DSGN (Design Pharma) - P/S Multiple|Rocket Corp (RCKT) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio 4D Molecular Therapeutics (FDMT)|LXEO - Price to Sales|P/S Multiple KRRO (Korro Bio)|EDIT: Market Cap to Revenue Ratio|SLN - Price-to-Revenue Ratio|PRQR (ProQR Therapeutics N.V.) - Market Cap to Revenue Ratio|CDXS: P/S Multiple|sangamo.com (SGMO) - P/S Multiple|Price-to-Revenue Ratio Nautilus Biotechnology, Inc.|Metagenomi Inc. - Price-to-Sales Ratio|P/S Multiple DTIL|GBIO (generationbio.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple BOLD (Boundless Bio, Inc.)|Price-to-Revenue Coefficient Exicure Inc. (XCUR)|IMNN - Price-to-Revenue Ratio|Price to Sales Mustang Bio, Inc.|RNAZ (transcodetherapeutics.com) - Market Cap to Revenue|Bionano Genomics - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Applied DNA Sciences|bluebirdbio.com - Price-to-Sales Ratio|P/S Multiple IPA|OMGA (Omega Therapeutics Inc) - Market Capitalization-to-Revenue Ratio|P/S Multiple OMIC (Singular Genomics Systems Inc)|P/S Multiple Regulus RGLS|SYRS - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio TBIO (telesisbio.com)|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Market Cap to Revenue Unity Biotechnology Inc.